Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Liabilities and Shareholders Equity (2017 - 2025)

Inspire Medical Systems (INSP) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $907.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 12.24% to $907.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 billion through Dec 2025, up 7.59% year-over-year, with the annual reading at $907.3 million for FY2025, 12.24% up from the prior year.
  • Liabilities and Shareholders Equity hit $907.3 million in Q4 2025 for Inspire Medical Systems, up from $807.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $907.3 million in Q4 2025 to a low of $272.2 million in Q2 2021.
  • Historically, Liabilities and Shareholders Equity has averaged $578.3 million across 5 years, with a median of $628.9 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: grew 0.33% in 2021 and later surged 111.73% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $295.1 million in 2021, then surged by 91.43% to $564.9 million in 2022, then rose by 19.82% to $676.8 million in 2023, then increased by 19.44% to $808.4 million in 2024, then increased by 12.24% to $907.3 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for INSP at $907.3 million in Q4 2025, $807.7 million in Q3 2025, and $802.2 million in Q2 2025.